NASDAQ:OMED - Oncomed Pharmaceuticals Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Oncomed Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.89 0.00 (0.00 %) (As of 02/25/2020 04:00 PM ET) Add Compare Today's Range$0.89Now: $0.89▼$0.8950-Day Range$0.89MA: $0.89▼$0.8952-Week Range$0.55Now: $0.89▼$3.35VolumeN/AAverage Volume768,904 shsMarket Capitalization$34.43 millionP/E RatioN/ADividend YieldN/ABeta1.86 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email OncoMed Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. It is developing Navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors; and Phase Ib clinical trials for patients with second-line metastatic colorectal cancer, as well as in Phase Ib clinical trial in patients with platinum-resistant ovarian cancer. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OMED Previous Symbol CUSIPN/A CIK1302573 Webhttp://www.oncomed.com/ Phone650-995-8200Debt Debt-to-Equity RatioN/A Current Ratio5.04 Quick Ratio5.04Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$44.42 million Price / Sales0.78 Cash FlowN/A Price / Cash FlowN/A Book Value$1.25 per share Price / Book0.71Profitability EPS (Most Recent Fiscal Year)($0.16) Net Income$-8,100,000.00 Net Margins-18.24% Return on Equity-13.14% Return on Assets-7.73%Miscellaneous Employees22 Outstanding Shares38,690,000Market Cap$34.43 million Next Earnings Date3/5/2020 (Estimated) OptionableOptionable Receive OMED News and Ratings via Email Sign-up to receive the latest news and ratings for OMED and its competitors with MarketBeat's FREE daily newsletter. Oncomed Pharmaceuticals (NASDAQ:OMED) Frequently Asked Questions What is Oncomed Pharmaceuticals' stock symbol? Oncomed Pharmaceuticals trades on the NASDAQ under the ticker symbol "OMED." How were Oncomed Pharmaceuticals' earnings last quarter? Oncomed Pharmaceuticals Inc (NASDAQ:OMED) released its earnings results on Thursday, November, 1st. The biopharmaceutical company reported $0.16 EPS for the quarter, beating the Zacks' consensus estimate of ($0.20) by $0.36. The biopharmaceutical company had revenue of $19.52 million for the quarter, compared to analysts' expectations of $7.97 million. Oncomed Pharmaceuticals had a negative return on equity of 13.14% and a negative net margin of 18.24%. View Oncomed Pharmaceuticals' Earnings History. When is Oncomed Pharmaceuticals' next earnings date? Oncomed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Oncomed Pharmaceuticals. Has Oncomed Pharmaceuticals been receiving favorable news coverage? News articles about OMED stock have trended very negative on Tuesday, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Oncomed Pharmaceuticals earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Oncomed Pharmaceuticals. Who are some of Oncomed Pharmaceuticals' key competitors? Some companies that are related to Oncomed Pharmaceuticals include Newron Pharmaceuticals (NWPHF), NuCana (NCNA), NeuBase Therapeutics (NBSE), Sierra Oncology (SRRA), ProMetic Life Sciences (PFSCF), Cassava Sciences (SAVA), Aravive (ARAV), Aldeyra Therapeutics (ALDX), Helix Biopharma (HBPCF), AcelRx Pharmaceuticals (ACRX), Chimerix (CMRX), CymaBay Therapeutics (CBAY), Galmed Pharmaceuticals (GLMD), TapImmune (MRKR) and Millendo Therapeutics (MLND). What other stocks do shareholders of Oncomed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oncomed Pharmaceuticals investors own include Esperion Therapeutics (ESPR), NXP Semiconductors (NXPI), GW Pharmaceuticals PLC- (GWPH), Nightstar Therapeutics (NITE), Celldex Therapeutics (CLDX), Verastem (VSTM), ImmunoGen (IMGN), Universal Display (OLED), Alnylam Pharmaceuticals (ALNY) and Celgene (CELG). Who are Oncomed Pharmaceuticals' key executives? Oncomed Pharmaceuticals' management team includes the folowing people: Mr. Perry A. Karsen, Exec. Chairman (Age 64)Ms. Jill Henrich, Sr. VP of Regulatory Affairs & Quality AssuranceDr. Ann Kapoun Ph.D., Sr. VP of Translational Medicine What is Oncomed Pharmaceuticals' stock price today? One share of OMED stock can currently be purchased for approximately $0.89. How big of a company is Oncomed Pharmaceuticals? Oncomed Pharmaceuticals has a market capitalization of $34.43 million and generates $44.42 million in revenue each year. The biopharmaceutical company earns $-8,100,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. Oncomed Pharmaceuticals employs 22 workers across the globe.View Additional Information About Oncomed Pharmaceuticals. What is Oncomed Pharmaceuticals' official website? The official website for Oncomed Pharmaceuticals is http://www.oncomed.com/. How can I contact Oncomed Pharmaceuticals? Oncomed Pharmaceuticals' mailing address is 800 Chesapeake Drive, Redwood City CA, 94063. The biopharmaceutical company can be reached via phone at 650-995-8200 or via email at [email protected] MarketBeat Community Rating for Oncomed Pharmaceuticals (NASDAQ OMED)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 313 (Vote Outperform)Underperform Votes: 253 (Vote Underperform)Total Votes: 566MarketBeat's community ratings are surveys of what our community members think about Oncomed Pharmaceuticals and other stocks. Vote "Outperform" if you believe OMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMED will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/25/2020 by MarketBeat.com StaffFeatured Article: Real Estate Investment Trust (REIT) ETF
